Acasti Pharma Inc
ACST.V
$0.580 1.75%
Exchange: TSXV | Sector: Healthcare | Industry: Biotechnology
Q3 2025
Published: Feb 13, 2025

Earnings Highlights

  • EPS of $-0.36 decreased by 12.5% from previous year
  • Net income of -4.16M
  • "N/A" -
ACST.V
Company ACST.V

Executive Summary

Acasti Pharma reported a Q3 2025 standing with no quarterly revenue and a material net loss driven primarily by ongoing R&D and general and administrative spend. Revenue remains absent in QQ3 2025, while operating expenses totaled approximately $3.704 million and R&D expense reached $2.194 million, contributing to an EBITDA of about -$3.702 million and a net income of -$4.156 million (-$0.36 per share). The company displays strong liquidity metrics, with a current ratio of 6.06 and a cash ratio of 5.61, underscoring balance sheet resilience despite the cash burn typical of a pre-revenue biotech. Management’s strategic focus continues to center on CaPre (the cardiovascular program) and pursuing strategic partnerships that could unlock near-term value through upfronts, milestones, or collaboration economics. Absent revenue, the near-term equity story hinges on successful partnerships or other value-enhancing strategic moves rather than operating leverage or margin expansion.

Key Performance Indicators

Operating Income
Increasing
-3.70M
QoQ: 23.33% | YoY: 8.13%
Net Income
Decreasing
-4.16M
QoQ: -21.07% | YoY: -73.78%
EPS
Decreasing
-0.36
QoQ: -20.00% | YoY: -12.50%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 0.00 -0.06 +0.0% View
Q1 2026 0.00 -0.21 +0.0% View
Q4 2025 0.01 0.05 +0.0% View
Q3 2025 0.00 -0.36 +0.0% View
Q2 2025 0.00 -0.30 +0.0% View